Reata Pharmaceuticals (NASDAQ:RETA) was upgraded by investment analysts at ValuEngine from a “hold” rating to a “buy” rating in a research report issued on Monday, February 4th.
RETA has been the subject of a number of other research reports. Cantor Fitzgerald set a $100.00 target price on shares of Reata Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, November 7th. BidaskClub lowered shares of Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, November 15th. Finally, Zacks Investment Research upgraded shares of Reata Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, October 10th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. Reata Pharmaceuticals has an average rating of “Buy” and an average price target of $100.33.
RETA stock opened at $96.93 on Monday. The stock has a market capitalization of $2.67 billion, a PE ratio of -33.77 and a beta of 3.15. The company has a debt-to-equity ratio of 2.10, a current ratio of 6.04 and a quick ratio of 6.04. Reata Pharmaceuticals has a 12 month low of $19.31 and a 12 month high of $99.50.
Reata Pharmaceuticals (NASDAQ:RETA) last posted its earnings results on Thursday, February 28th. The company reported ($0.86) EPS for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.21. As a group, analysts anticipate that Reata Pharmaceuticals will post -4.39 EPS for the current year.
In related news, insider Keith Wayne Ward sold 15,183 shares of the firm’s stock in a transaction that occurred on Monday, February 25th. The shares were sold at an average price of $91.00, for a total value of $1,381,653.00. Following the completion of the transaction, the insider now owns 23,803 shares in the company, valued at approximately $2,166,073. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Jason Douglas Wilson sold 20,000 shares of the stock in a transaction that occurred on Monday, January 7th. The shares were sold at an average price of $72.04, for a total transaction of $1,440,800.00. Following the sale, the chief financial officer now directly owns 20,000 shares of the company’s stock, valued at approximately $1,440,800. The disclosure for this sale can be found here. In the last quarter, insiders purchased 169,731 shares of company stock valued at $10,041,717 and sold 61,483 shares valued at $4,791,177. 31.69% of the stock is owned by company insiders.
A number of large investors have recently added to or reduced their stakes in RETA. Franklin Resources Inc. increased its position in Reata Pharmaceuticals by 223.6% during the 3rd quarter. Franklin Resources Inc. now owns 859,013 shares of the company’s stock valued at $70,233,000 after purchasing an additional 593,552 shares during the period. Point72 Asset Management L.P. increased its position in Reata Pharmaceuticals by 276.6% during the 3rd quarter. Point72 Asset Management L.P. now owns 749,800 shares of the company’s stock valued at $61,304,000 after purchasing an additional 550,706 shares during the period. Vanguard Group Inc increased its position in Reata Pharmaceuticals by 75.1% during the 3rd quarter. Vanguard Group Inc now owns 1,187,632 shares of the company’s stock valued at $97,101,000 after purchasing an additional 509,326 shares during the period. Vanguard Group Inc. increased its position in Reata Pharmaceuticals by 75.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,187,632 shares of the company’s stock valued at $97,101,000 after purchasing an additional 509,326 shares during the period. Finally, BlackRock Inc. increased its position in Reata Pharmaceuticals by 28.2% during the 3rd quarter. BlackRock Inc. now owns 1,928,362 shares of the company’s stock valued at $157,663,000 after purchasing an additional 424,582 shares during the period. 53.65% of the stock is owned by institutional investors and hedge funds.
Reata Pharmaceuticals Company Profile
Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases with therapies by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl for the treatment of patients with chronic kidney disease caused by Alport syndrome; and for a form of pulmonary arterial hypertension associated with connective tissue disease.
Recommended Story: What are the most popular ETFs
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.